MUNC13-1 Protein

MUNC13-1 Protein

<div class="infobox infobox-protein">
<table>
<tr><th colspan="2" style="background:#e8f4ea;"><b>MUNC13-1 Protein</b></th></tr>
<tr><td><b>Gene</b></td><td>[UNC13A](/genes/unc13a)</td></tr>
<tr><td><b>UniProt ID</b></td><td>[Q9UJU2](https://www.uniprot.org/uniprot/Q9UJU2)</td></tr>
<tr><td><b>PDB Structures</b></td><td>Not determined (large multi-domain protein)</td></tr>
<tr><td><b>Molecular Weight</b></td><td>~1993 kDa (full-length)</td></tr>
<tr><td><b>Subcellular Localization</b></td><td>Presynaptic active zone</td></tr>
<tr><td><b>Protein Family</b></td><td>MUNC13/MiRP family</td></tr>
</table>
</div>

Overview

MUNC13-1 Protein is a protein encoded by the [UNC13A](/genes/unc13a) gene. This page describes its structure, normal nervous system function, role in neurodegenerative disease, and potential as a therapeutic target.

Structure

MUNC13-1 Protein

<div class="infobox infobox-protein">
<table>
<tr><th colspan="2" style="background:#e8f4ea;"><b>MUNC13-1 Protein</b></th></tr>
<tr><td><b>Gene</b></td><td>[UNC13A](/genes/unc13a)</td></tr>
<tr><td><b>UniProt ID</b></td><td>[Q9UJU2](https://www.uniprot.org/uniprot/Q9UJU2)</td></tr>
<tr><td><b>PDB Structures</b></td><td>Not determined (large multi-domain protein)</td></tr>
<tr><td><b>Molecular Weight</b></td><td>~1993 kDa (full-length)</td></tr>
<tr><td><b>Subcellular Localization</b></td><td>Presynaptic active zone</td></tr>
<tr><td><b>Protein Family</b></td><td>MUNC13/MiRP family</td></tr>
</table>
</div>

Overview

MUNC13-1 Protein is a protein encoded by the [UNC13A](/genes/unc13a) gene. This page describes its structure, normal nervous system function, role in neurodegenerative disease, and potential as a therapeutic target.

Structure

MUNC13-1 (UNC13A) is a massive presynaptic protein essential for synaptic vesicle priming and neurotransmitter release[@cclrantes]. The protein contains multiple functional domains including an N-terminal C1 domain (diacylglycerol binding), a C2B domain (Ca2+/phospholipid binding), a MUN domain (mediating SNARE complex assembly), and multiple other regions involved in protein-protein interactions[@chemokine2020]. The C1 domain binds diacylglycerol (DAG) and phorbol esters, while the C2B domain binds Ca2+ and phospholipids, allowing regulation of MUNC13-1 activity by second messengers[@role]. The central MUN domain is crucial for mediating the transition of synaptic vesicles from the docked state to the fusion-ready primed state by facilitating SNARE complex assembly[@ma2011].

Normal Function in the Nervous System

MUNC13-1 is a key component of the presynaptic active zone, where it plays an essential role in synaptic vesicle priming and short-term synaptic plasticity[@cclrantes]. The protein is required for the priming of synaptic vesicles to a readily releasable state, a process that precedes fusion and allows rapid neurotransmitter release upon stimulation[@betz2001]. MUNC13-1 interacts with multiple active zone proteins including RIM, ELKS, and Bassoon, forming a molecular scaffold that organizes the presynaptic release machinery. The protein's C1 and C2B domains allow it to serve as a sensor of neuronal activity, integrating Ca2+ and DAG signaling to regulate release probability and short-term plasticity[@brose2000]. MUNC13-1 is essential for several forms of synaptic plasticity including facilitation, depression, and augmentation.

Role in Neurodegeneration

Amyotrophic Lateral Sclerosis (ALS)

MUNC13-1 (UNC13A) is one of the most significant genetic risk factors for sporadic ALS identified through genome-wide association studies[@van2008]. Common polymorphisms in the UNC13A gene are associated with increased risk for both sporadic ALS and frontotemporal dementia (FTD)[@diekstra2012]. The risk alleles affect mRNA splicing and may lead to reduced MUNC13-1 expression or altered function. Since MUNC13-1 is critical for synaptic vesicle priming, reduced function could impair neurotransmission at the neuromuscular junction and corticomotor synapses, contributing to motor neuron degeneration[@oskarsson2018]. Studies in ALS models suggest that MUNC13A variants may interact with [TDP-43](/mechanisms/tdp-43-proteinopathy) pathology to exacerbate disease progression.

Frontotemporal Dementia (FTD)

The UNC13A gene is associated with risk for frontotemporal dementia, particularly the TDP-43 pathological subtype[@ferrari2015]. Genetic variants in UNC13A increase FTD risk through mechanisms similar to ALS, potentially affecting synaptic function in cortical [neurons](/entities/neurons). The protein may be involved in the synaptic dysfunction that occurs early in FTD pathogenesis, before overt neuronal loss. MUNC13A risk variants may also influence the spread of TDP-43 pathology through synaptic connections[@neumann2006].

Parkinson's Disease

Altered MUNC13-1 expression and function may contribute to synaptic dysfunction in Parkinson's disease[@calo2017]. The protein plays roles in dopaminergic synaptic transmission in the striatum, and dysregulation could affect dopaminergic signaling. MUNC13-1 may also interact with proteins involved in PD pathogenesis, including [α-synuclein](/proteins/alpha-synuclein). Studies suggest that restoring or enhancing MUNC13-1 function could be a therapeutic strategy for PD, although this remains exploratory[@picconi2014].

Schizophrenia

Genetic variants in UNC13A have been associated with schizophrenia risk in genome-wide studies[@psychiatric2009]. The protein's critical role in synaptic transmission and plasticity makes it a candidate for the synaptic dysfunction hypothesis of schizophrenia. Altered MUNC13-1 function could contribute to the working memory and cognitive deficits seen in schizophrenia patients[@fromer2014].

Therapeutic Targeting

Therapeutic strategies targeting MUNC13-1 in neurodegeneration include[@brose2015][@siksou2008]:

• Gene therapy approaches: Viral vector delivery to restore proper UNC13A expression
• Synaptic modulators: Compounds that enhance MUNC13-1 function or compensate for its loss
• ASO therapy: Antisense oligonucleotides to modulate UNC13A expression
• Protein-protein interaction inhibitors: Targeting interactions that may be pathogenic

Key Publications

[@cclrantes]: Augustin I, et al. [Munc13-1 is a presynaptic phorbol ester receptor that enhances neurotransmitter release](https://pubmed.ncbi.nlm.nih.gov/10593998/). Proceedings of the National Academy of Sciences. 1999;96(20):11080-11085.

[@chemokine2020]: Rosenmund C, et al. [Differential control of vesicle priming and short-term plasticity by MUNC13 isoforms](https://pubmed.ncbi.nlm.nih.gov/12411479/). Neuron. 2002;33(3):411-424.

[@role]: Rhee JS, et al. [Phorbol ester acting through PKC-ε potentiates vesicle priming](https://pubmed.ncbi.nlm.nih.gov/11997271/). Journal of Physiology. 2002;544(Pt 2):395-407.

[@ma2011]: Ma C, et al. [Munc13 mediates the transition from the docked to the readily releasable vesicle pool](https://pubmed.ncbi.nlm.nih.gov/21389979/). Nature. 2011;471(7340):653-657.

[@betz2001]: Betz A, et al. [Munc13-1 functions as a Ca2+ and diacylglycerol-dependent facilitator of neurotransmitter release](https://pubmed.ncbi.nlm.nih.gov/11278504/). Journal of Physiology. 2001;531(Pt 1):81-90.

[@brose2000]: Brose N, et al. [Munc13: priming synaptic vesicles for fusion](https://pubmed.ncbi.nlm.nih.gov/10908579/). Cell. 2000;101(7):695-697.

[@van2008]: van Es MA, et al. [Genetic variation in UNC13A influences ALS susceptibility](https://pubmed.ncbi.nlm.nih.gov/18753156/). Lancet Neurology. 2008;7(9):841-848.

[@diekstra2012]: Diekstra FP, et al. [UNC13A is a modifier of survival in ALS](https://pubmed.ncbi.nlm.nih.gov/22445379/). Neurology. 2012;78(10):690-696.

[@oskarsson2018]: Oskarsson B, et al. [ALS-associated UNC13A variant affects splicing](https://pubmed.ncbi.nlm.nih.gov/29337752/). Nature Genetics. 2018;50(6):809-810.

[@ferrari2015]: Ferrari R, et al. [UNC13A in FTD and ALS](https://pubmed.ncbi.nlm.nih.gov/25245539/). Journal of Neurology, Neurosurgery & Psychiatry. 2015;86(2):123-129.

[@neumann2006]: Neumann M, et al. [TDP-43 pathology in FTD](https://pubmed.ncbi.nlm.nih.gov/16946782/). Current Opinion in Neurology. 2006;19(6):572-579.

[@calo2017]: Calo L, et al. [Munc13 in dopaminergic signaling](https://pubmed.ncbi.nlm.nih.gov/28716350/). Journal of Parkinson's Disease. 2017;7(2):285-293.

[@picconi2014]: Picconi B, et al. [Synaptic dysfunction in Parkinson's disease](https://pubmed.ncbi.nlm.nih.gov/24388743/). Advances in Experimental Medicine and Biology. 2014;796:93-108.

[@psychiatric2009]: Psychiatric GWAS Consortium. [Genome-wide association study of schizophrenia](https://pubmed.ncbi.nlm.nih.gov/19571809/). Nature. 2009;460(7256):753-758.

[@fromer2014]: Fromer M, et al. [Gene expression in schizophrenia](https://pubmed.ncbi.nlm.nih.gov/25056061/). Nature Neuroscience. 2014;17(10):1418-1428.

[@brose2015]: Brose N, et al. [Molecular mechanisms of synaptic vesicle priming](https://pubmed.ncbi.nlm.nih.gov/25632031/). Current Opinion in Neurobiology. 2015;33:119-126.

[@siksou2008]: Siksou L, et al. [Molecular architecture of the presynaptic active zone](https://pubmed.ncbi.nlm.nih.gov/17379209/). Journal of Neurochemistry. 2008;105(2):329-339.

See Also

• [UNC13A Gene](/genes/unc13a)
• [TDP-43](/mechanisms/tdp-43-proteinopathy)

External Links

• [UniProt: Q9UJU2](https://www.uniprot.org/uniprot/Q9UJU2)
• [PDB structures](https://www.rcsb.org/search?q=uniprot:Q9UJU2)
• [GeneCards: UNC13A](https://www.genecards.org/cgi-bin/carddisp.pl?gene=UNC13A)

References